Jennifer M. Specht, MD (IMAGE)
Caption
The FEATURE study provides the first prospective validation of FDG-PET/CT and PERCIST response criteria in patients presenting with bone-only or bone-dominant metastatic breast cancer, opening the potential to inform patients about whether their treatment is working, rather than waiting for late-stage disease progression,” said Jennifer M. Specht, MD, a medical oncologist at the University of Washington and Fred Hutch Cancer Center.
Credit
Fred Hutch Cancer Center
Usage Restrictions
No restrictions.
License
Public Domain